Atkinson et al. conducted a retrospective study, DESCRIBE II, consisting of a chart review of patients with BRAF V600-mutated unresectable stage III/IV melanoma receiving dabrafenib plus trametinib as compassionate use. The gene discussed is BRAF; the disease is melanoma.